KLK3 and posterior cortical atrophy: The 352 patients in the LIGHTHOUSE study with newly diagnosed PCa had a median age of 65 y and a median PSA of 8.8 ng/mL, and 32% of those patients were considered to have unfavorable intermediate-risk disease.